Cargando…
Elinzanetant (NT-814), a Neurokinin 1,3 Receptor Antagonist, Reduces Estradiol and Progesterone in Healthy Women
CONTEXT: The ideal therapy for endometriosis (EM) and uterine fibroids (UFs) would suppress estrogenic drive to the endometrium and myometrium, while minimizing vasomotor symptoms and bone loss associated with current treatments. An integrated neurokinin-kisspeptin system involving substance P and n...
Autores principales: | Pawsey, Steve, Mills, Edouard Gregory, Ballantyne, Elizabeth, Donaldson, Kirsteen, Kerr, Mary, Trower, Mike, Dhillo, Waljit Singh |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8277204/ https://www.ncbi.nlm.nih.gov/pubmed/33624806 http://dx.doi.org/10.1210/clinem/dgab108 |
Ejemplares similares
-
SUN-LB58 Repeated Once-Daily Administration of the Non-Hormonal Neurokinin 1,3 Receptor Antagonist NT-814 Reduces LH, Estradiol and Progesterone in Healthy Women
por: Dhillo, Waljit Singh, et al.
Publicado: (2020) -
Effects of NT-814, a dual neurokinin 1 and 3 receptor antagonist, on vasomotor symptoms in postmenopausal women: a placebo-controlled, randomized trial
por: Trower, Mike, et al.
Publicado: (2020) -
Efficacy and safety of elinzanetant, a selective neurokinin-1,3 receptor antagonist for vasomotor symptoms: a dose-finding clinical trial (SWITCH-1)
por: Simon, James A., et al.
Publicado: (2023) -
OR11-03 NT-814, a Non-Hormonal Dual Neurokinin 1,3 Receptor Antagonist Markedly Improves Vasomotor Symptoms in Post-Menopausal Women; Results of a Randomised, Double-Blind, Placebo-Controlled, Dose-Finding Study (SWITCH-1)
por: Simon, James, et al.
Publicado: (2020) -
Treating hot flushes with a neurokinin 3 receptor antagonist
por: Prague, Julia K., et al.
Publicado: (2017)